Partner With Us
BLOOD-BASED BIOMARKERS & DIAGNOSTICS

Healthy Mitochondria for Healthy Aging

Mitochondrial dysfunction is the defining hallmark of aging and the root cellular cause of neurodegenerative disorders like Alzheimer’s and Parkinson’s. MyToHealth develops proprietary blood-based diagnostic biomarkers (pUB) and therapeutic discovery platforms to detect cellular damage early and restore mitochondrial integrity.
Explore pUB Platform
Partner With Us
Blood-Based
NON-INVASIVE DIAGNOSTIC SCREEN
pUB
PROPRIETARY FLAGSHIP BIOMARKER
PD & AD
TARGETING NEURODEGENERATIVE ONSET
Malvern, PA
RESEARCH & DISCOVERY FACILITIES
Collaboration Models

Audience Pathways

Collaborating with scientific leaders, clinical diagnostic providers, and patient research foundations.

Pharma & Biotech Partners

Access our validated E3 ubiquitin ligase toolbox, assay development protocols, and small-molecule therapeutic discovery pipelines targeting mitophagy.
Explore Partnership

Research Foundations

Partnering with patient cohorts (such as the Michael J. Fox Foundation) to validate poly-ubiquitin biomarkers for longitudinal progression studies.
Collaborate on Research

Diagnostic & Clinical Labs

Deploying high-throughput, blood-based diagnostic assays (e.g., LabCorp and reference laboratories) for rapid, cost-effective detection of neurodegeneration.
Inquire for Testing
Flagship Innovation

The pUB Blood-Based Biomarker Platform

Currently, there are no effective, routine blood-based tests to diagnose early-stage Parkinson’s and Alzheimer’s diseases. MyToHealth’s proprietary technology isolates and enriches minute poly-ubiquitinated structures from human blood, establishing a definitive signature for neurodegeneration.
  • Selective Poly-Ubiquitin Enrichment: Patented affinity matrices designed to capture unique ubiquitin chain linkages directly from patient serum.
  • Early Detection Capability: Identifying compromised mitophagy pathways before irreversible neuronal cell death occurs.
  • Therapeutic Evaluation Tool: Assisting clinicians and pharmaceutical sponsors in evaluating patient response to next-generation PD/AD therapies.
Request Biomarker Data

Diagnosing Before Neuronal Loss

In diseases like Parkinson’s, alpha-synuclein and damaged organelles accumulate due to failure of the Ubiquitin Proteasome System (UPS).
Mutations in Parkin and PINK1 kinase paralyze the cell’s quality control checks. Our platform decodes these cellular stress signals from peripheral blood samples, bringing diagnostic clarity to up to one million patients in the US alone.
Biological Mechanisms

Diseased Mitochondria: The Root Cause

Understanding the cellular quality control machinery that sustains neuronal energy and prevents degeneration.
PILLAR 01

Mitochondrial Dynamics

Mitochondria produce over 90% of cellular energy (ATP). Due to extreme metabolic demands, neurons are particularly susceptible to mitochondrial depolarization, leading to rapid energy collapse, memory loss, and motor dysfunction.

PILLAR 02

Mitophagy & Biogenesis

Cellular homeostasis requires removing damaged mitochondria (Mitophagy) and generating new organelles (Mitobiogenesis). Modulating these pathways with small molecules restores mitochondrial density and protects against sarcopenia and neuronal death.

PILLAR 03

Ubiquitin Proteasome System (UPS)

The UPS cascade acts as the master guardian of cellular health. E3 ligases mark damaged mitochondrial proteins with poly-ubiquitin chains, orchestrating organellar degradation and activating nuclear mitochondrial gene transcription.

Scientific Credibility

Key Research Publications

Peer-reviewed literature supporting our mitochondrial quality control and ubiquitin ligase discovery platforms.

The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
Research Paper
Age on Autophagy, Mitophagy and Lysosomes in Skeletal Muscle
Review Article
Assessment of Heterogeneity in Parkinson’s Progression Markers Initiative (PPMI) Cohort
Clinical Study
E3 Overexpression Protects from Ageing-Related Loss of Muscle Mass and Strength
Therapeutic Mechanism

Collaborate With MyToHealth

Connect directly with our Business Development team in Malvern, PA to discuss biomarker licensing, assay access, or collaborative research.
Business DevelopmentSarah Thomas
Inquiries Emailbd@mytohealth.net
Contact Business Development